AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03247803 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Williams Airway Intubator (WA)
Description: WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
Study NCT02155153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sugar Free Chewing Gum
Description: 'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
Study NCT01394094 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gum chewing
Description: Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
Study NCT03029364 — intervention group
Intervention type: BEHAVIORAL
Intervention: Study Protocol
Description: Participants will complete three study protocols 7 - 28 days apart which includes:~* 3 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.~* 2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.~* Maintenance of habitual habits, dietary and physical activity behaviour patterns~We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. The current study does not involve an intervention.
Study NCT02694653 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
Study NCT02694653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen
Description: 1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
Study NCT03772860 — intervention group
Intervention type: OTHER
Intervention: Pain stimulation
Description: Pain will be simulated with an electric shock 25 mlAMP over the median nerve
Study NCT03772860 — intervention group
Intervention type: OTHER
Intervention: Visual stimulation
Description: Visual stimulation will be performed by a flicker of light on a computer screen at 15 Hrz for 0.3 seconds
Study NCT03772860 — intervention group
Intervention type: OTHER
Intervention: Auditory stimulation
Description: Auditory stimulation will be delivered through headphones with a sound at 500 Hrz at 85 decibels for 0.3 seconds
Study NCT03772860 — intervention group
Intervention type: OTHER
Intervention: Mental stress
Description: A mathematical challenge will be displayed on a computer screen that must be quickly solved
Study NCT00582283 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: I124-NM404
Description: I-124-NM404
Study NCT02530567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention
Description: All patients performing the biopsy will have an MRI to carry out the necessary measures.
Study NCT01643603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Patients receive dasatinib PO every day (QD) for 6 months.
Study NCT01643603 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT05631288 — intervention group
Intervention type: GENETIC
Intervention: Sampe collection
Description: Unstimulated crevicular fluid samples are collected using two sized 35 paper cones per subject, both used in the sampling process. The DNA is extracted from the samples through multiplex PCR at the Egas Moniz Applied Microbiology Laboratory (LMAEM).
Study NCT03487003 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rocuronium
Description: After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg rocuronium is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues.
Study NCT03487003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Description: After standard anesthetic monitoring (non-invasive blood pressure monitor, pulse oximetry, 3-lead echocardiography), patients are inhaled with sevoflurane. When the patients asleep, 0.3 mg/kg saline is administered. After 2 min, flexible laryngeal mask airway (fLMA) is inserted using standard method. The fLMA is inflated with air to 40 cmH2O using manometry. The oropharyngeal leak pressure (OLP) was determined by the method described by Lopez-Gil and colleagues
Study NCT06373562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypoxia
Description: The athletes were living in hypoxic rooms, which could simulate a selected altitude above sea level.
Study NCT03250377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: * Pharmaceutical form: Film-coated tablet~* Concentration: 25 mg and 50 mg~* Route of administration: Oral use
Study NCT03838250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cellgram™ (Bone marrow-derived MSCs)
Description: Approximately 15 to 30 mL of bone marrow is aspirated from the posterior iliac crest of patients under local anesthesia. Approximately 30 days (±7 days) after BM aspiration, the participant will return to the study center for admission and for the infusion Cellgram™ (Bone marrow-derived MSCs).
Study NCT03370367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13-cis retinoic acid
Description: Taken daily.
Study NCT03370367 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01272180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.
Description: Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
Study NCT01272180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
Description: Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
Study NCT01272180 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
Description: One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
Study NCT01272180 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.
Description: Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
Study NCT05342831 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological Nutrition Technique
Description: Biological nutrition technique woman trying Biological feeding technique was applied after each breastfeeding. Breastfeeding self-efficacy and breastfeeding success were assessed at regular intervals.
Study NCT00676559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efalizumab
Description: Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
Study NCT00676559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
Study NCT00850772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early post-operative enteral feeding
Description: During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
Study NCT01109706 — intervention group
Intervention type: OTHER
Intervention: biological parameters dosage
Description: 200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).~After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).~Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up.
Study NCT02162875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praziquantel
Description: Six different treatment strategies with praziquantel
Study NCT01640743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Methylprednisolone
Description: Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.~Maintenance therapy:~Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
Study NCT01640743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus + Everolimus + Methylprednisolone
Description: Induction therapy:~Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).~Maintenance therapy:~Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels
Study NCT03574545 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ianalumab
Description: Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
Study NCT03574545 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ianalumab
Description: Human monoclonal antibody (mAb) of type IgG1/κ binding to B-cell activating-receptor (BAFF-R)
Study NCT00629304 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
Study NCT00629304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VISITS + PDA-FIT system
Description: patients will have face to face visits at 3 and 6 months + PDA-FIT system
Study NCT00629304 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PDA-FIT System + telephone follow-up
Description: patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
Study NCT03521362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyT1DHero
Description: MyT1DHero is an app with two separate interfaces, one for the parent and one for the child, that work together to help them communicate about diabetes management. The child receives system reminders to enter their blood glucose numbers, and parents receive a notification about each blood glucose test their child enters. Parents are also able to use the app to communicate with their child about their plan for care. The app has customizable blood glucose reminders and ranges, videos of support from other adolescents with T1D, snack lists, and other educational information on T1D.
Study NCT03521362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Other T1D Mobile App
Description: A mobile app will be used in this control/comparison group that only has blood sugar testing reminders and logging capabilities. There will be no other components of the app.
Study NCT03497858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut Water
Description: participants will consume coconut water and complete a simulated basketball game
Study NCT03497858 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo - water
Description: participants will consume Placebo - water and complete a simulated basketball game
Study NCT03497858 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sports drink
Description: participants will consume a sports drink and complete a simulated basketball game
Study NCT04289805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: letrozole is orally administered (5mg/d) from cycle day 2-3 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering.~Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist.
Study NCT04289805 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard-stimulated cohort
Description: Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol.~Standard Protocol: Gonadotrophins started from cycle day 2-3 throughout the ovarian stimulation until ovulation triggering.~Random start protocol: Gonadotrophins started at any time of the cycle and throughout the stimulation.~GnRH antagonist is administered at cycle day 7 or as soon as at least one follicle reaches 12-14 mm.~Oocytes are collected 36h after ovulation triggering with GnRH agonist.
Study NCT00921674 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Description: Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
Study NCT01127113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of investigational product
Description: The investigational product will be delivered via intravenous infusion
Study NCT01127113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Infusion of investigational product
Description: The investigational product will be delivered via intravenous infusion
Study NCT01127113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
Study NCT01127113 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cardiac magnetic resonance imaging
Description: Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
Study NCT02888964 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add-on therapy
Description: Pioglitazone therapy
Study NCT02757287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FSH-CTP + DESOGESTREL
Description: Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)~- Quality of Life questionnaire the day after the bolus
Study NCT01530997 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Description: All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
Study NCT01530997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
Study NCT01530997 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Limited surgical evaluation
Description: 4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
Study NCT03791697 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telehealth 2 week postoperative visit
Description: The patient randomized into the telephone follow up group, will be contacted, at the pre-scheduled date and time, by the urogynecology clinic nurse. The nurse will utilize a scripted series of postoperative questions, which are consistent with questions asked during our standard postoperative clinic visits.~Vital signs and physical examination will be deferred for the patients in the telephone follow up group.~Any patient responses that are not consistent with a usual postoperative course will be escalated to an in person visit. However, these patients will remain in the group, to which they were originally randomized, for research analysis purposes. (Intent to treat)
Study NCT04060251 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyMedica e-vive™ System; CY-1000
Description: All the patients in Group 2 will be given the CyMedica Orthopedics e-vive system 3 weeks before the surgery. The patients will begin using the unit after their first pre-intervention measurements are taken.~Patients will be instructed to apply the e-vive NMES Strength therapy twice a day, 5 days a week. The NMES Strength program is 20 minutes in length. Treatment intensity (adjustable from 1 to 100 in NMES programs) is required to be set at the highest tolerable limit for the patients.~Stimulation from the garment will have the following parameters: frequency of 50 Hz; pulse duration of 5 ms; time on: 12.8 seconds; and time off: 10 seconds. The total contraction time in a 20-minute treatment will be 11 minutes. The waveform will be pulsed and asymmetrical.
Study NCT04060251 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iGetBetter telemedicine physical therapy
Description: Group 1 patients will only use a Post-Op program from iGetBetter for the first 3 weeks after surgery. After those 3 weeks have elapsed, Group 1 patients will receive outpatient physical therapy in addition to iGetBetter, approximately twice per week for the next 6-8 weeks as all other groups.
Study NCT03948854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Registered dietitian
Description: Education on low FODMAP diet is provided in person by a registered dietitian who is an expert on the low FODMAP diet
Study NCT03948854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-line video program
Description: Education on low FODMAP diet is provided by an on-line program via a link sent through email
Study NCT03948854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Printed handout
Description: Education on low FODMAP diet is provided through printed handout material at the initial visit.
Study NCT00771147 — intervention group
Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
Study NCT01103518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethinyl Estradiol + Cyproterone acetate
Description: Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
Study NCT01103518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol + Cyproterone acetate
Description: Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
Study NCT03948854 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietitian-led group
Description: Education on low FODMAP diet is provided in a dietitian-led group setting
Study NCT03306758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Bicarbonate
Description: Sodium Bicarbonate was given 1g tid for one month
Study NCT02933060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline (1000 mL)
Study NCT02933060 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control